Rohit kohli

Has grant

Division Chief

Children's Hospital of Los Angeles

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Rohit Kohli is the Division Chief at the Children's Hospital of Los Angeles, USA. His research primarily focuses on pediatric liver diseases, including metabolic dysfunction-associated steatotic liver disease, and the impact of socioeconomic factors on clinical outcomes in children with acute liver failure. He has authored several articles addressing innovative therapies for pediatric non-alcoholic steatohepatitis (NASH), as well as the management of metabolic liver disease.

Recent Grants

Grant: Close

Candidate selection of a LPAR1 antagonist for therapeutic application in NASH

Open Date: 2021-09-20

Close Date: 2025-06-30

Grant: Close

NAFLD Improvement after Bariatric Surgery: The role of bile acid signaling

Open Date: 2015-04-01

Close Date: 2020-03-31

Grant: Close

Limited Competition for the Continuation of the Childhood Liver Disease Research Network (ChilLDRen) Clinical Centers.

Open Date: 2009-09-10

Close Date: 2024-05-31

Grant: Close

Role of Ileum in Reducing Obesity Related Comorbidities

Open Date: 2009-09-01

Close Date: 2013-08-31

Articles (12)

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

Adjunct Assistant Professor

University of Southern California

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Rohit kohli

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (12)

Integrated workflow for analysis of immune enriched spatial proteomic data with IMmuneCite

AASLD Practice Statement on the evaluation and management of metabolic dysfunction–associated steatotic liver disease in children

Finance, race, ethnicity, and spoken language impact clinical outcomes for children with acute liver failure

Lysophosphatidic acid receptor 1 antagonist (EPGN2154) causes regression of NASH in preclinical NASH models

Dietary Management of Metabolic Liver Disease

Model for End‐Stage Liver Disease/Pediatric End‐Stage Liver Disease exception policy and outcomes in pediatric patients with hepatopulmonary syndrome requiring liver transplantation

Impact of long‐term administration of maralixibat on children with cholestasis secondary to Alagille syndrome

Pediatric NASH therapies: A speedbump on the road to success

Nature or Nurture in the Pathogenesis of Biliary Atresia?

Exposure to per- and Polyfluoroalkyl Substances and Markers of Liver Injury: A Systematic Review and Meta-Analysis

Stratification by obesity class, rather than age, can identify a higher percent of children at risk for non‐alcoholic fatty liver disease and metabolic dysfunction

PNPLA3 Genotype, Arachidonic Acid Intake, and Unsaturated Fat Intake Influences Liver Fibrosis in Hispanic Youth with Obesity

Collaborators (7)

Darryl Hwang

Roshonda Jones

Juliet Emamaullee

Douglas Walker

Fabio C Tucci

Evanthia Roussos Torres

Tanya Alderete

Make your next move.